

From: Stephen.Rabinowitz@WolfGreenfield.com
To: [Trials](#)
Cc: eellison-ptab@sternekessler.com; cgallo-ptab@sternekessler.com; opartington-ptab@sternekessler.com; SRabinowitz-PTAB@WolfGreenfield.com; JVanAmsterdam-PTAB@WolfGreenfield.com
Subject: Takeda Vaccines, Inc. v. Valneva Austria GmbH - Case No. IPR2023-00354
Date: Wednesday, March 22, 2023 4:56:55 PM
Attachments: [I042270125US01-SD-JRV.PDF](#)

CAUTION: This email has originated from a source outside of USPTO. **PLEASE CONSIDER THE SOURCE** before responding, clicking on links, or opening attachments.

RE: Takeda Vaccines, Inc. v. Valneva Austria GmbH
Case No. IPR2023-00354

Dear Honorable Board,

The attached Statutory Disclaimer Under 37 CFR 1.321(a) was filed yesterday with the U.S. Patent and Trademark Office. Patent Owner disclaimed claims 1-15 and 21-25 of U.S. Patent No. 11,219,681 and, therefore, no challenged claims remain in IPR2023-00354.

Please let us know if any additional filings are necessary to request termination of IPR2023-00354.

Thank you

 **Stephen S. Rabinowitz**
Counsel
212-849-3356
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue | Boston, MA 02210
605 Third Avenue | New York, NY 10158
Stephen.Rabinowitz@wolfgreenfield.com | wolfgreenfield.com | [in](#) [twitter](#)

This e-mail message and any attachments may contain confidential or privileged information. If you are not the intended recipient, please notify me immediately by replying to this message. Please destroy all copies of this message and any attachments. Thank you.